Outbreak of metabolic dysfunction-associated steatohepatitis pharmacotherapies in 2024:From resmetirom to tirzepatide  

作　　者：Rui Huang Chunli Zhang Xiaodong Mo Huiying Rao 

机构地区：[1]Peking University People’s Hospital,Peking University Hepatology Institute,Infectious Disease and Hepatology Center of Peking University People’s Hospital,Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases,Beijing International Cooperation Base for Science and Technology on NAFLD Diagnosis,Beijing 100044,China [2]Department of Hematology,Beijing Hospital,National Center of Gerontology,Institute of Geriatric Medicine,Chinese Academy of Medical Sciences,Beijing 100730,China [3]Peking University People’s Hospital,Department of Hematology,Peking University Institute of Hematology,National Clinical Research Center for Hematologic Disease,Beijing 100044,China

出　　处：《Chinese Medical Journal》2025年第2期127-129,共3页中华医学杂志(英文版)

基　　金：supported by the National Key Research&Development Program of China(No.2022YFA1303804);Peking University People’s Hospital Scientific Research Development Funds(No.RDJ2022-21);Peking University Hepatology Institute Qi-Min Project.

摘　　要：Metabolic dysfunction-associated steatotic liver disease(MASLD)is an increasingly common chronic liver disease with a global prevalence among adults exceeding 30%and approximately 1.66 billion cases worldwide as of 2019.[1]Metabolic dysfunction-associated steatohepatitis(MASH)is one of the most aggressive subtypes of MASLD and is associated with an elevated risk of cardiovascular disease,advanced liver fibrosis,and increased liver-related and all-cause morbidity and mortality.The estimated global prevalence of MASH is>5%with approximately 39.9 million cases reported in 2019.[1]The incidence of hepatic decompensation,hepatocellular carcinoma,and deaths linked to MASH cirrhosis is projected to rise twofold to threefold by 2030.[2]Although weight loss leads to histological improvements,only 25%and 19%of patients achieve resolution of MASH and improvement in fibrosis,respectively.Additionally,achieving and sustaining weight loss is challenging and 20%of patients regain weight.[3]Resmetirom,a thyroid hormone receptor-beta(THRβ)agonist,is the only drug approved by the US Food and Drug Administration(FDA)for MASH with significant liver fibrosis(stage≥2);however,the conditional approval is local and no pharmacotherapy is currently recommended for MASH at the cirrhotic stage.[4]Therefore,effective medications for MASH are urgently required.

关 键 词：chronic liver disease tirzepatide liver disease masld pharmacotherapies resmetirom 

分 类 号：R575.5[医药卫生—消化系统]